Roche's IMpower130 Met Co-Primary Endpoints, Lifting ASCO Suspense

 
• By Sten Stovall

Roche said its Phase III IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in the advanced first-line setting for non-squamous lung cancer.

Doctor examining at lungs radiograph x-ray film of patient in operation room. medical concept.
Roche Says Tecentriq In IMpower130 Met OS and PFS Co-Primary Endpoints • Source: Shutterstock

More from Immuno-oncology

More from Anticancer